New York Comprehensive Thalassemia Center
Found 65 results
Author [ Title(Desc)] Type Year
Filters: First Letter Of Last Name is S  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Stacy S, Sheth S, Coleman B, Cerenzia W.  2021.  An assessment of the continuing medical education needs of US physicians in the management of patients with beta thalassemia.. Ann Hematol. 100(1):27-35.
Stacy S, Sheth S, Coleman B, Cerenzia W.  2021.  An assessment of the continuing medical education needs of US physicians in the management of patients with beta thalassemia.. Ann Hematol. 100(1):27-35.
Goel R, Patel EU, Cushing MM, Frank SM, Ness PM, Takemoto CM, Vasovic LV, Sheth S, Nellis ME, Shaz B et al..  2018.  Association of Perioperative Red Blood Cell Transfusions With Venous Thromboembolism in a North American Registry.. JAMA Surg. 153(9):826-833.
Goel R, Patel EU, Cushing MM, Frank SM, Ness PM, Takemoto CM, Vasovic LV, Sheth S, Nellis ME, Shaz B et al..  2018.  Association of Perioperative Red Blood Cell Transfusions With Venous Thromboembolism in a North American Registry.. JAMA Surg. 153(9):826-833.
B
Nellis ME, Levasseur J, Stribling J, E Faustino VS, Zantek ND, Sheth S, Karam O.  2019.  Bleeding Scales Applicable to Critically Ill Children: A Systematic Review.. Pediatr Crit Care Med. 20(7):603-607.
Nellis ME, Levasseur J, Stribling J, E Faustino VS, Zantek ND, Sheth S, Karam O.  2019.  Bleeding Scales Applicable to Critically Ill Children: A Systematic Review.. Pediatr Crit Care Med. 20(7):603-607.
Fassel H, Sheth S.  2020.  Bone Marrow Failure in Children: Approach to Diagnosis and Treatment.. Indian J Pediatr. 87(2):141-149.
C
Al-Samkari H, van Beers EJ, D Morton H, Barcellini W, Eber SW, Glader B, Yaish HM, Chonat S, Kuo KHM, Kollmar N et al..  2020.  Characterization of the severe phenotype of pyruvate kinase deficiency.. Am J Hematol.
Al-Samkari H, van Beers EJ, D Morton H, Barcellini W, Eber SW, Glader B, Yaish HM, Chonat S, Kuo KHM, Kollmar N et al..  2020.  Characterization of the severe phenotype of pyruvate kinase deficiency.. Am J Hematol.
Weiss M, Jun MParisi, Sheth S.  2019.  Clinical and economic burden of regularly transfused adult patients with β-thalassemia in the United States: A retrospective cohort study using payer claims.. Am J Hematol. 94(5):E129-E132.
Grace RF, Bianchi P, van Beers EJ, Eber SW, Glader B, Yaish HM, Despotovic JM, Rothman JA, Sharma M, McNaull MM et al..  2018.  Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study.. Blood. 131(20):2183-2192.
Grace RF, Bianchi P, van Beers EJ, Eber SW, Glader B, Yaish HM, Despotovic JM, Rothman JA, Sharma M, McNaull MM et al..  2018.  Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study.. Blood. 131(20):2183-2192.
Boscoe AN, Yan Y, Hedgeman E, van Beers EJ, Al-Samkari H, Barcellini W, Eber SW, Glader B, Yaish HM, Chonat S et al..  2021.  Comorbidities and complications in adults with pyruvate kinase deficiency.. Eur J Haematol. 106(4):484-492.
Boscoe AN, Yan Y, Hedgeman E, van Beers EJ, Al-Samkari H, Barcellini W, Eber SW, Glader B, Yaish HM, Chonat S et al..  2021.  Comorbidities and complications in adults with pyruvate kinase deficiency.. Eur J Haematol. 106(4):484-492.
Frangoul H, Altshuler D, M Cappellini D, Chen Y-S, Domm J, Eustace BK, Foell J, de la Fuente J, Grupp S, Handgretinger R et al..  2021.  CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.. N Engl J Med. 384(3):252-260.
Frangoul H, Altshuler D, M Cappellini D, Chen Y-S, Domm J, Eustace BK, Foell J, de la Fuente J, Grupp S, Handgretinger R et al..  2021.  CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.. N Engl J Med. 384(3):252-260.
Frangoul H, Altshuler D, M Cappellini D, Chen Y-S, Domm J, Eustace BK, Foell J, de la Fuente J, Grupp S, Handgretinger R et al..  2021.  CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.. N Engl J Med. 384(3):252-260.
Frangoul H, Altshuler D, M Cappellini D, Chen Y-S, Domm J, Eustace BK, Foell J, de la Fuente J, Grupp S, Handgretinger R et al..  2021.  CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.. N Engl J Med. 384(3):252-260.
E
Hoshino A, Kim HSang, Bojmar L, Gyan KEnnu, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S et al..  2020.  Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.. Cell. 182(4):1044-1061.e18.
Hoshino A, Kim HSang, Bojmar L, Gyan KEnnu, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S et al..  2020.  Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.. Cell. 182(4):1044-1061.e18.
Hoshino A, Kim HSang, Bojmar L, Gyan KEnnu, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S et al..  2020.  Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.. Cell. 182(4):1044-1061.e18.
Hoshino A, Kim HSang, Bojmar L, Gyan KEnnu, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S et al..  2020.  Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.. Cell. 182(4):1044-1061.e18.
Hoshino A, Kim HSang, Bojmar L, Gyan KEnnu, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S et al..  2020.  Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.. Cell. 182(4):1044-1061.e18.
Hoshino A, Kim HSang, Bojmar L, Gyan KEnnu, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S et al..  2020.  Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.. Cell. 182(4):1044-1061.e18.
Hoshino A, Kim HSang, Bojmar L, Gyan KEnnu, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S et al..  2020.  Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.. Cell. 182(4):1044-1061.e18.